Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Simsen Diagnostics AB manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The data shows 2 pending office actions currently active. These matters are spread across a corresponding number of distinct examiners and 2 distinct art units, reflecting a broader technical footprint than a single-unit portfolio.
The busiest examiner, PHAM, KHAI QUYNH TIEN, is responsible for 1 busiest examiner pending office action. With the total workload divided, the company is currently interfacing with different examiners across multiple art units. This may require distinct tactical approaches for each Biotechnology & Pharmaceuticals application depending on the specific examiner's requirements.
Practitioners should note that the presence of multiple art units for the active cases indicates that each matter is being treated under different technical guidelines. The 2 pending office actions represent the entirety of the current prosecution workload. This distribution requires the applicant to monitor separate examination tracks simultaneously to ensure consistent progress.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PHAM, KHAI QUYNH TIEN | 1 | 0.0% | +0.0% |
| YOUNG, BRIAN ELLIS | 1 | 65.8% | +24.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18556183 | COMPOSITIONS AND METHODS FOR CELL-FREE NUCLEIC ACID ISOLATION | PHAM, KHAI QUYNH TIEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18001080 | LYMPHOCYTE CLONALITY DETERMINATION | YOUNG, BRIAN ELLIS | 15d |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18556183 | COMPOSITIONS AND METHODS FOR CELL-FREE NUCLEIC ACID ISOLATION | PHAM, KHAI QUYNH TIEN | 1682 | §102§103 | Non-Final OA | — | Pending | Oct 19, 2023 |
| 18001080 | LYMPHOCYTE CLONALITY DETERMINATION | YOUNG, BRIAN ELLIS | 1684 | §103DP | Final Rejection | 15d | Pending | Dec 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial